- Home
- HOOK vs AEHL Comparison
HOOK vs AEHL Comparison
Compare HOOK & AEHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HOOK
- AEHL
- Stock Information
- Founded
- HOOK 2011
- AEHL 1993
- Country
- HOOK United States
- AEHL China
- Employees
- HOOK N/A
- AEHL N/A
- Industry
- HOOK Biotechnology: Pharmaceutical Preparations
- AEHL Building Materials
- Sector
- HOOK Health Care
- AEHL Industrials
- Exchange
- HOOK Nasdaq
- AEHL Nasdaq
- Market Cap
- HOOK 11.9M
- AEHL 13.9M
- IPO Year
- HOOK 2019
- AEHL 2007
- Fundamental
- Price
- HOOK $0.89
- AEHL $3.48
- Analyst Decision
- HOOK Hold
- AEHL
- Analyst Count
- HOOK 3
- AEHL 0
- Target Price
- HOOK $4.50
- AEHL N/A
- AVG Volume (30 Days)
- HOOK 155.2K
- AEHL 612.7K
- Earning Date
- HOOK 08-11-2025
- AEHL 09-29-2025
- Dividend Yield
- HOOK N/A
- AEHL N/A
- EPS Growth
- HOOK N/A
- AEHL N/A
- EPS
- HOOK N/A
- AEHL N/A
- Revenue
- HOOK $9,351,000.00
- AEHL $98,773,000.00
- Revenue This Year
- HOOK N/A
- AEHL N/A
- Revenue Next Year
- HOOK N/A
- AEHL N/A
- P/E Ratio
- HOOK N/A
- AEHL N/A
- Revenue Growth
- HOOK N/A
- AEHL 36.99
- 52 Week Low
- HOOK $0.72
- AEHL $1.79
- 52 Week High
- HOOK $6.00
- AEHL $174.00
- Technical
- Relative Strength Index (RSI)
- HOOK 19.78
- AEHL 50.02
- Support Level
- HOOK $0.89
- AEHL $3.02
- Resistance Level
- HOOK $0.95
- AEHL $6.53
- Average True Range (ATR)
- HOOK 0.06
- AEHL 0.68
- MACD
- HOOK -0.01
- AEHL -0.08
- Stochastic Oscillator
- HOOK 7.11
- AEHL 23.94
About HOOK HOOKIPA Pharma Inc.
HOOKIPA Pharma Inc is a clinical-stage biopharmaceutical company developing a class of immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform that is designed to reprogram the body's immune system. Its oncology portfolio targets oncoviral cancer antigens and next-generation antigens and includes two primary programs in development: eseba-vec (formerly HB-200) and HB-700. Eseba-vec is in clinical development for the treatment of Human Papillomavirus 16-positive (HPV16+) head and neck cancers. It also develops infectious disease therapies in partnership with other companies. Its Hepatitis B (HBV) program, HB-400, and Human Immunodeficiency Virus (HIV) program, HB-500, are being developed in partnership with Gilead.
About AEHL Antelope Enterprise Holdings Limited
Antelope Enterprise Holdings Ltd operates in two reportable operating segments: 1) business management consulting, information system technology consulting services including the sales of software use rights for digital data deposit platforms and asset management systems, and online social media platform development and consulting, and 2) natural gas power generation, which was in the initial development stage. The business of the Company is engaged in the PRC and U.S.